medigraphic.com
SPANISH

Acta Médica Grupo Angeles

Órgano Oficial del Hospital Angeles Health System
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
    • Send manuscript
    • Names and affiliations of the Editorial Board
  • Policies
  • About us
    • Data sharing policy
    • Stated aims and scope
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2020, Number 2

<< Back Next >>

Acta Med 2020; 18 (2)

Angiomyofibroblastoma as a cause of transvaginal bleeding

Ochoa CFJ, Hernández AJF, Cázares RTK, Martínez LAC
Full text How to cite this article 10.35366/93894

DOI

DOI: 10.35366/93894
URL: https://dx.doi.org/10.35366/93894

Language: Spanish
References: 10
Page: 188-190
PDF size: 198.41 Kb.


Key words:

Vaginal angiomyofibroblastoma, transvaginal bleeding, tumorectomy, female genital tract stromal tumors.

ABSTRACT

The angiomyofibroblastoma is a low incidence entity that belongs to the stromal tumours of the female reproductive system, the most frequent location is the vulvar one. Even when it has a favorable prognosis, it represents a diagnostic challenge due to the lack of consensus criteria and the variety of histological data and immunohistochemical markers. We report the case of a surgical postmenopausal patient attending emergency room for postcoital bleeding and hemodynamic instability, with an evident hyperintense vaginal cuff tumor on the T2 magnetic resonance. Being treated with surgical resection, with adequate clinical evolution. Vaginal localization of angiomyofibroblastoma is unusual, with just 7 cases reported till 2004 by Kaberi.


REFERENCES

  1. Fletcher CD, Tsang WY, Fisher C, Lee KC, Chan JK. Angiomyofibroblastoma of the vulva. A benign neoplasm distinct from aggressive angiomyxoma. Am J Surg Patho. 1992; 16: 373-382.

  2. Horvai A, Link T. “Angiomyofibroblastoma”. In: Bone and soft tissue pathology: high-yield pathology. E.U.A.: Saunders, Elsevier; 2012. pp. 315-316.

  3. Nucci M. Mesenchymal lesions of the lower genital tract. Surg Pathol Clin. 2009; 2 (4): 603-623.

  4. McCluggage W. Immunohistochemical markers of value in the diagnosis of mesenchymal lesions of the female genital tract. Surg Pathol Clin. 2009; 2 (4): 785-811.

  5. McCluggage W, White RG. Angiomyofibroblastoma of the vagina. J Clin Pathol. 2000; 53: 803-806.

  6. Banerjee K, Datta Gupta S, Mathur SR. Vaginal angiomyofibroblastoma. Arch Gynecol Obstet. 2004; 270 (2): 124-125.

  7. Magro G, Righi A, Caltabiano R, Casorzo L, Michal M. Vulvovaginal angiomyofibroblastomas: morphologic, immunohistochemical, and fluorescence in situ hybridization analysis for deletion of 13q14 region. Hum Pathol. 2014; 45 (8): 1647-1655.

  8. Geng J, Hu S, Wang F. Large paravaginal angiomyofibroblastoma: magnetic resonance imaging findings. Jpn J Radiol. 2011; 29: 152-155.

  9. Lee H, Jeng C, Ko M, Huang S, Chen S. Vulvar Angiomyofibroblastoma. J Obstet Gynecol. 2008; 47 (2): 220-221.

  10. Magro G, Caltabiano R, Kacerovská D, Vecchio GM, Kazakov D, Michal M. Vulvovaginal myofibroblastoma: expanding the morphological and immunohistochemical spectrum. A clinicopathologic study of 10 cases. Hum Pathol. 2012; 43 (2): 243-253.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Acta Med. 2020;18